Takeda Shares Promising Interim Results For Mezagitamab In IgA Nephropathy
I'm PortAI, I can summarize articles.
Takeda Pharmaceutical Company Limited (TAK) announced promising interim results from its Phase 1b trial of mezagitamab (TAK-079) for IgA nephropathy. The study showed stable kidney function, measured by estimated glomerular filtration rate (eGFR), maintained through Week 96, up to 18 months post-treatment. These findings were presented at the ASN Kidney Week 2025 in Houston. IgA nephropathy is a progressive autoimmune disease affecting young individuals, with no current cure and a significant risk of renal failure.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments